Mechanisms of mesenchymal stromal cell immunomodulation

Immunology and Cell Biology

Volumn 91, Issue 1, 2013, Pages 19-26

  English, Karen ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

cell contact; immune modulation; mesenchymal stromal cells; soluble factors; tolerogenic DC; Treg

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; APOPTOSIS; CELL MIGRATION; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; DENDRITIC CELL; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; REVIEW; TH1 TH2 BALANCE; TH17 CELL; TH2 CELL; TISSUE REPAIR;

ANIMALS; APOPTOSIS; CLONAL ANERGY; HUMANS; INFLAMMATION; MESENCHYMAL STROMAL CELLS; REGENERATIVE MEDICINE; T-LYMPHOCYTES, REGULATORY; TISSUE THERAPY;

EID: 84872144085     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.56     Document Type: Review

References (100)

1. Friedenstein AJ, Chailakhj, RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3: 393-403.
2. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230-247.
3. Saldanha-Araujo F, Ferreira FI, Palma PV, Araujo AG, Queiroz RH, Covas DT et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. Stem Cell Res 2011; 7: 66-74.
4. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48. (Pubitemid 34059216)
5. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843. (Pubitemid 34534559)
6. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 2011; 118: 330-338.
7. Cutler AJ, Limbani V, Girdlestone J, Navarrete CV. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol 2010; 185: 6617-6623.
8. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 2008; 115: 50-58. (Pubitemid 350298590)
9. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol 2009; 37: 1445-1453.
10. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
11. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490. (Pubitemid 43242385)
12. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T et al. Mesenchymal-stem-cellinduced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544-555.
13. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90: 1312-1320.
14. Kong QF, Sun B, Bai SS, Zhai DX, Wang GY, Liu YM et al. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGFbeta. J Neuroimmunol 2009; 207: 83-91.
15. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23: 1196-1202. (Pubitemid 351767482)
16. Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 2011; 66: 523-531.
17. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745-1755.
18. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150. (Pubitemid 351181031)
19. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801. (Pubitemid 43261452)
20. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
21. Medzhitov R. Inflammation 2010: New adventures of an old flame. Cell 2010; 140: 771-776.
22. Lee MJ, Kim J, Kim MY, Bae YS, Ryu SH, Lee TG et al. Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J Proteome Res 2010; 9: 1754-1762.
23. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Ylostalo J, Coble K et al. Action at a distance: Systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells 2011; 29: 1572-1579.
24. Qiu Y, Marquez-Curtis LA, Janowska-Wieczorek A. Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q. Cytotherapy 2012; 14: 285-295.
25. Schraufstatter IU, Discipio RG, Zhao M, Khaldoyanidi SK. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol 2009; 182: 3827-3836.
26. Liu H, Liu S, Li Y, Wang X, Xue W, Ge G et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 2012; 7: E34608.
27. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25: 1737-1745. (Pubitemid 47121852)
28. Carrero R, Cerrada I, Lledo E, Dopazo J, Garcia-Garcia F, Rubio MP et al. IL1beta Induces Mesenchymal Stem Cells Migration and Leucocyte Chemotaxis Through NF-kappaB. Stem Cell Rev 2012; 8: 905-916.
29. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010; 5: E10088.
30. Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008; 180: 2581-2587.
31. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398. (Pubitemid 44464808)
32. Ren G, Su J, Zhang L, Zhao X, Ling W, L'Huillie A et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-1962.
33. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007; 110: 91-100. (Pubitemid 46830943)
34. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27: 909-919.
35. Sioud M, Mobergslien A, Boudabous A, Floisand Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol 2010; 71: 267-274.
36. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26: 279-289.
37. Romieu-Mourez R, Francois M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009; 182: 7963-7973.
38. Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lonnies L et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One 2011; 6: E21703.
39. Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev 2010; 19: 1803-1809.
40. Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles for multipotent, bone marrowderived stromal cells in host defense. Blood 2012; 119: 1801-1809.
41. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
42. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 2012; 122: 787-795.
43. Francois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012; 20: 187-195.
44. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010; 5: E9252.
45. Zhang QZ, Su WR, Shi SH, Wilder-Smith P, Xiang AP, Wong A et al. Human gingivaderived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells 2010; 28: 1856-1868.
46. Giunti D, Parodi B, Usai C, Vergani L, Casazza S, Bruzzone S et al. Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1. Stem Cells 2012; 30: 2044-2053.
47. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S et al. Stem/ progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA 2008; 105: 14638-14643.
48. Ylostalo JH, Bartosh TJ, Coble K, Prockop DJ. Human mesenchymal stem/stromal cells (hMSCs) cultured as spheroids are self-activated to produce prostaglandin E2 (PGE2) that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 2012; 30: 2283-2296.
49. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol Today 1999; 20: 469-473. (Pubitemid 29476077)
50. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353-363. (Pubitemid 47063057)
51. Tatara R, Ozaki K, Kikuchi Y, Hatanaka K, Oh I, Meguro A et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 2011; 13: 686-694.
52. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333. (Pubitemid 351213419)
53. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-150. (Pubitemid 34178297)
54. Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM et al. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 2011; 41: 2840-2851.
55. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010; 5: E14247.
56. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
57. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010; 264: 171-179.
58. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
59. Brown JM, Nemeth K, Kushnir-Sukhov NM, Metcalfe DD, Mezey E. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy 2011; 41: 526-534.
60. Oh JY, Lee RH, Yu JM, Ko JH, Lee HJ, Ko AY et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther. (e-pub ahead of print 28 August 2012; doi:10.1038/mt.2012.165).
61. Lim JH, Kim JS, Yoon IH, Shin JS, Nam HY, Yang SH et al. Immunomodulation of delayed-type hypersensitivity responses by mesenchymal stem cells is associated with bystander T cell apoptosis in the draining lymph node. J Immunol 2010; 185: 4022-4029.
62. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234. (Pubitemid 46053063)
63. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110: 3691-3694. (Pubitemid 350159638)
64. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4 + T cells. Science 2010; 327: 1098-1102.
65. Zhou L, Chong MM, Littman DR. Plasticity of CD4 + T cell lineage differentiation. Immunity 2009; 30: 646-655.
66. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD et al. Human bone marrowderived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57: 1192-1203.
67. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009; 183: 993-1004.
68. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2: 34.
69. English K, French A, Wood KJ. Mesenchymal stromal cells: Facilitators of successful transplantation? Cell Stem Cell 2010; 7: 431-442.
70. English K, Mahon BP. Allogeneic mesenchymal stem cells: Agents of immune modulation. J Cell Biochem 2011; 112: 1963-1968.
71. Batten P, Sarathchandra P, Antoniw JW, Tay SS, Lowdell MW, Taylor PM et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: Relevance to tissue engineering human heart valves. Tissue Eng 2006; 12: 2263-2273. (Pubitemid 44734984)
72. Goodwin M, Sueblinvong V, Eisenhauer P, Ziats NP, LeClair L, Poynter ME et al. Bone marrow-derived mesenchymal stromal cells inhibit Th2-mediated allergic airways inflammation in mice. Stem Cells 2011; 29: 1137-1148.
73. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versushost disease: Clinical report. Biol Blood Marrow Transplant 2010; 16: 403-412.
74. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185: 302-312.
75. Chen L, Zhang W, Yue H, Han Q, Chen B, Shi M et al. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev 2007; 16: 719-731. (Pubitemid 350125233)
76. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032. (Pubitemid 47258180)
77. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087. (Pubitemid 44200965)
78. Li YP, Paczesny S, Lauret E, Poirault S, Bordigoni P, Mekhloufi F et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 2008; 180: 1598-1608.
79. Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009; 113: 46-57.
80. Chiesa S, Morbelli S, Morando S, Massollo M, Marini C, Bertoni A et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 2011; 108: 17384-17389.
81. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9: 1760-1772.
82. Liu X, Qu X, Chen Y, Liao L, Cheng K, Shao C et al. Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol 2012; 189: 1182-1192.
83. Cvetanovich GL, Hafler DA. Human regulatory T cells in autoimmune diseases. Curr Opin Immunol 2010; 22: 753-760.
84. Nadig SN, Wieckiewicz J, Wu DC, Warnecke G, Zhang W, Luo S et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809-813.
85. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417-430.
86. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009; 182: 5994-6002.
87. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 +CD25(high) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
88. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 +CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222.
89. Tasso R, Ilengo C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53: 786-793.
90. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181: 3933-3946.
91. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008; 20: 55-60.
92. Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc 2009; 41: 4352-4356.
93. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652-5657.
94. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, Eljaafari A et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52: 1391-1399.
95. Zhao W, Wang Y, Wang D, Sun B, Wang G, Wang J et al. TGF-beta expression by allogeneic bone marrow stromal cells ameliorates diabetes in NOD mice through modulating the distribution of CD4 + T cell subsets. Cell Immunol 2008; 253: 23-30.
96. Zhang Q, Shi S, Liu Y, Uyanne J, Shi Y, Le AD. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183: 7787-7798.
97. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W et al. Inflammatory cytokineinduced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010; 184: 2321-2328.
98. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-1490. (Pubitemid 40691430)
99. Sioud M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol 2011; 73: 79-84.
100. Meisel R, Brockers S, Heseler K, Degistirici O, Bulle H, Woite C et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011; 25: 648-654.